E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Phenylketonuria (PKU) is an autosomal recessive metabolic genetic disorder by a mutation in the gene for the enzyme phenylalanine hydroxylase (PAH), rendering it nonfunctional. Left untreated, the disease will result in high concentrations of phenylalanine (Phe) in blood and tissues, likely resulting in severe mental retardation and behavioural problems. Treatment focusus on the restriction of dietary phenylalanine intake with supplementation of a synthetic phenylalaninefree amino acid mixture. |
|
E.1.1.1 | Medical condition in easily understood language |
Phenylketonuria (PKU) is an autosomal recessive metabolic genetic disorder. Untreated, PKU can lead to mental retardation and behavioural problems. |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Nutritional and Metabolic Diseases [C18] |
MedDRA Classification |
E.1.3 | Condition being studied is a rare disease | Yes |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To measure the effect of sapropterin on diurnal and day to day variations of blood phenylalanine concentrations. |
|
E.2.2 | Secondary objectives of the trial |
- To measure the effect of sapropterin on diurnal and day to day variations of blood tyrosine concentrations.
- To measure the effect of sapropterin on diurnal and day to day variations of blood phenylalanine/tyrosine ratios. |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Males and females 4-12 years of age.
- Diagnosed with phenylketonuria by newborn screening.
- Tested to be sapropterin responsive.
- Under good metabolic control; defined as 2/3 or 67% of the blood phenylalanine levels within target ranges during the last year.
|
|
E.4 | Principal exclusion criteria |
- Concomitant disease which may preclude the participation in the study in the judgment of the investigator.
- Intercurrent illness which might influence the blood phenylalanine levels.
- Concomitant medication as mentioned in the Kuvan® SPC.
- Known hypersensitivity to Kuvan® or its excipients.
- Known hypersensitivity to other approved or non-approved formulations of tetrahydrobiopterin.
- Non-compliance with study procedures in the judgement of the investigator. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
The mean standard deviations of the blood phenylalanine concentrations measured four times a day of 2 consecutive days and once a day on 8 consecutive days of all participants compared between the sapropterin + diet treatment period and the diet alone treatment period. |
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
In both study periods blood sampling is scheduled for the first six days once a day (7-8 am) and four times daily (7-8 am, 12-1 pm, 5-6 pm and bedtime) on the two days thereafter, in total 28 samples per patient. |
|
E.5.2 | Secondary end point(s) |
- The mean standard deviations of the blood tyrosine concentrations measured once a day on 8 consecutive days of all participants compared between the sapropterin + diet treatment period and the diet alone treatment period.
- The mean standard deviations of the blood tyrosine concentrations measured four times a day of 2 consecutive days of all participants compared between the sapropterin + diet treatment period and the diet alone treatment period.
- The mean standard deviations of the blood phenylalanine/tyrosine ratios measured once a day on 8 consecutive days of all participants compared between the sapropterin + diet treatment period and the diet alone treatment period.
- The mean standard deviations of the blood phenylalanine/tyrosine concentrations measured four times a day of 2 consecutive days of all participants compared between the sapropterin + diet treatment period and the diet alone treatment period. |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
In both study periods blood sampling is scheduled for the first six days once a day (7-8 am) and four times daily (7-8 am, 12-1 pm, 5-6 pm and bedtime) on the two days thereafter, in total 28 samples per patient. |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | No |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | No |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | Yes |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 4 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.7 | Trial has a data monitoring committee | Yes |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The sponsor will notify the accredited METc and the competent authority of the end of the study within a period of 90 days. The end of the study is defined as the last patient finishes the second blood phenylalanine and tyrosine 8 days measuring period.
In case the study is ended prematurely, the sponsor will notify the accredited METc and the competent authority within 15 days, including the reasons for the premature termination. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 2 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |